The ORIENT-32 clinical trial evaluated the efficacy and safety of sintilimab, a selective anti-PD-1 antibody (Gao et al., 2020), in combination with bevacizumab biosimilar in the treatment of unresectable HCC (Ren et al., 2021). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.